Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | WDR5 | P61964 | 1/20 | 0.42 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29489770 | 1.00 | HSD17B10 (0.44) | HSD17B10ALDH1A1TSHRCYP2A6TDP1 | |
| SCHEMBL29489771 | 1.00 | HSD17B10 (0.44) | HSD17B10ALDH1A1TSHRCYP2A6TDP1 | |
| SCHEMBL29583333 | 0.85 | TSHR (0.39) | HSD17B10ALDH1A1TSHRCYP2A6TDP1 | |
| SCHEMBL2079041 | 0.85 | TSHR (0.39) | HSD17B10ALDH1A1TSHRCYP2A6TDP1 | |
| SCHEMBL29583781 | 0.82 | MAPT (0.40) | HSD17B10ALDH1A1TSHRCYP2A6TDP1 | |
| SCHEMBL1925968 | 0.82 | MAPT (0.40) | HSD17B10ALDH1A1TSHRCYP2A6TDP1 | |
| Hydrochloric Acid SCHEMBL7943424 | 0.82 | RAB9A (0.40) | HSD17B10ALDH1A1TSHRCYP2A6TDP1 | |
| Hydrochloric Acid SCHEMBL7943427 | 0.82 | TSHR (0.37) | HSD17B10ALDH1A1TSHRCYP2A6TDP1 | |
| SCHEMBL24864996 | 0.82 | WDR5 (0.34) | WDR5DNMT1 | |
| SCHEMBL1925137 | 0.81 | GAA (0.38) | HSD17B10ALDH1A1TSHRCYP2A6TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111909065-B | Method for alpha-methylation of aryl benzyl sulfone compound | 浙江工业大学 | 2022-04-22 | — | — | CN | claimed |
| CN-111909065-A | Method for alpha-methylation of aryl benzyl sulfone compound | 浙江工业大学 | 2020-11-10 | — | — | CN | claimed |
| EP-3040337-B1 | 2, 6-DI-NITROGEN-CONTAINING SUBSTITUTED PURINE DERIVATIVE, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | ZHEJIANG MED XINCHANG PHARM (CN) | 2019-04-17 | — | — | EP | claimed |
| CN-108948021-A | A kind of support method replaces the preparation method of cloth | 山东罗欣药业集团恒欣药业有限公司 | 2018-12-07 | — | — | CN | claimed |
| CN-108299347-A | A kind of method that one pot of conversion furfural, 5 hydroxymethyl furfural prepare furans | 南昌大学 | 2018-07-20 | — | — | CN | claimed |
| CN-107056636-A | A kind of Oseltamivir derivative and its preparation method and application | 山东大学 | 2017-08-18 | — | — | CN | claimed |
| US-9718823-B2 | 2, 6-Di-nitrogen-containing substituted purine derivative, and preparation method, pharmaceutical composition and use thereof | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2017-08-01 | — | — | US | claimed |
| CN-105399744-B | A kind of Ao Gelieting synthetic method | 黄燕鸽 | 2017-07-18 | — | — | CN | claimed |
| CN-105906544-A | S-type 3-hydroxy-3-alkynyloxoindole compound and synthetic method and application thereof | 上海交通大学 | 2016-08-31 | — | — | CN | claimed |
| US-20160207924-A1 | 2, 6-Di-Nitrogen-Containing Substituted Purine Derivative, And Preparation Method, Pharmaceutical Composition And Use Thereof | ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2016-07-21 | — | — | US | claimed |
| EP-3040337-A1 | 2, 6-DI-NITROGEN-CONTAINING SUBSTITUTED PURINE DERIVATIVE, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory (CN) | 2016-07-06 | — | — | EP | claimed |
| CN-105399744-A | Synthetic method for omarigliptin | HUANG YANGE | 2016-03-16 | — | — | CN | claimed |
| EP-2149574-B1 | 2, 6-DINITROGEN-CONTAINING SUBSTITUTED PURINE DERIVATIVES, THE PREPARATION AND USES THEREOF | ZHEJIANG MED XINCHANG PHARM (CN) | 2015-12-02 | — | — | EP | claimed |
| US-8580763-B2 | 2, 6-dinitrogen-containing substituted purine derivatives, the preparation and uses thereof | ZHANGGUI WU (CN) | 2013-11-12 | — | — | US | claimed |
| US-20100144663-A1 | 2, 6-Dinitrogen-Containing Substituted Purine Derivatives, The Preparation And Uses Thereof | ZHE JIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICAL FACTORY (CN) | 2010-06-10 | — | — | US | claimed |
| EP-2149574-A1 | 2, 6-DINITROGEN-CONTAINING SUBSTITUTED PURINE DERIVATIVES, THE PREPARATION AND USES THEREOF | ZheJiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory (CN) | 2010-02-03 | — | — | EP | claimed |
| EP-4748839-A1 | POLYCYCLIC COMPOUND AND USE THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137699-A1 | OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| US-5563295-A | HYDROGENATION OF OLEFINIC CARBOXYLIC ACID USING RUTHENIUM-PHOSPHINE COMPLEX CATALYST | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1996-10-08 | — | — | US | disclosed |
| EP-0673911-A1 | Process for producing optically active carboxylic acids and chiral ligands for this purpose | Takasago International Corporation (JP) | 1995-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207924-A1 | 2, 6-Di-Nitrogen-Containing Substituted Purine Derivative, And Preparation Method, Pharmaceutical Composition And Use Thereof | NUDT1, PNP, SLC29A2 | HSD17B10 3968/4885ALDH1A1 693/4885TSHR 4657/4885 |
| US-20100144663-A1 | 2, 6-Dinitrogen-Containing Substituted Purine Derivatives, The Preparation And Uses Thereof | PNP, NUDT1, DPYD | HSD17B10 3467/4885ALDH1A1 254/4885TSHR 4632/4885 |
| US-20260137699-A1 | OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | SCN1B, OXER1, NR3C2 | HSD17B10 732/4885ALDH1A1 970/4885TSHR 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.